Bavarian Nordic Receives EMA Approval Of Mpox Vaccine For Adolescents; Approval Extends Current Marketing Authorization To Include Adolescents 12 To 17 Years Of Age; Clinical Trial To Assess Immunogenicity, Safety Of MVA-BN In Children 2-12 Years Is...

Benzinga · Sep 19 21:54

Bavarian Nordic Receives EMA Approval Of Mpox Vaccine For Adolescents; Approval Extends Current Marketing Authorization To Include Adolescents 12 To 17 Years Of Age; Clinical Trial To Assess Immunogenicity, Safety Of MVA-BN In Children 2-12 Years Is Expected To Start Next Month

- Reuters

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Bavarian Nordic Receives EMA Approval Of Mpox Vaccine For Adolescents; Approval Extends Current Marketing Authorization To Include Adolescents 12 To 17 Years Of Age; Clinical Trial To Assess Immunogenicity, Safety Of MVA-BN In Children 2-12 Years Is...

Bavarian Nordic Receives EMA Approval Of Mpox Vaccine For Adolescents; Approval Extends Current Marketing Authorization To Include Adolescents 12 To 17 Years Of Age; Clinical Trial To Assess Immunogenicity, Safety Of MVA-BN In Children 2-12 Years Is Expected To Start Next Month

Risk Disclaimer